Advanced Oxygen Therapy

TWO2 delivers high oxygen penetration (800 mmHg) to non-healing wounds, supporting metabolism, collagen production, and immune response.

Topical Wound Oxygen (TWO2) is a clinically proven, non-invasive therapy for chronic and difficult-to-heal wounds, usable at home.

Clinical Evidence Archive - Advanced Oxygen Therapy Inc.

The page lists frequently asked questions about AOTI, TWO2 therapy, and educational videos for healthcare professionals and wound care.

The page offers video tutorials and testimonials for AOTI’s products.

The page shares the latest news, publications, and research about AOTI and TWO2 therapy.

AOTI Regulatory News

Advanced Oxygen Therapy Inc. offers careers in healthcare innovation.

Anthony joined AOTI in January of 2009 as Director of Finance and Customer Service. He now serves as the company’s Chief Operating Officer. Prior to AOTI,

Douglas serves as a non-executive director for Advanced Medical Solutions, Revival Healthcare Capital Partners, Trio Healthcare, Clinisupplies, and The Insides Company Ltd.

DP Team Members Archive - Advanced Oxygen Therapy Inc.

Dr. Matthew G. Garoufalis, DPM, is a podiatric physician and wound care specialist serving as Chief Medical Officer of Advanced Oxygen Therapy, Inc.

AOTI treats chronic non-healing and acute complex wounds using advanced wound care, including topical hyperbaric oxygen and venous leg ulcers.

Preventing unnecessary amputations for diabetic patients through enhancing education and healthcare accessibility.

The NEXA product is protected by pending and granted patents globally:

The page provides contact information for inquiries about AOTI, TWO2 therapy, and wound care solutions.

3512 Seagate Way Suite 100 Oceanside, CA 92056 United States of America

Committed to durable wound healing with proven long-term reductions in DFU recurrence, hospitalizations, and amputations, resulting in reductions to total cost of care

Learn about our commitment to protecting your privacy and personal information.

Data protection is of a particularly high priority for the management of the Advanced Oxygen Therapy, Inc.

We use text messaging to provide important updates, reminders, appointments and information related to your use of TWO2 therapy.

Read our terms of service and understand our policies and practices for using our website and products.

AOTI Inc. announces a medical breakthrough in treating diabetic foot ulcers and chronic wounds under the leadership of Dr. Mike Griffiths. The company’s research focuses on accelerating healing for patients with hard-to-treat conditions. AOTI’s innovations aim to improve outcomes in wound care, addressing a significant unmet need in diabetes management.

Jan 2025Proactiveinvestors NANews article

AOTI secures a five-year extension for its contract with the U.S. Department of Veterans Affairs. The renewal continues the company’s work supporting veterans’ healthcare services under the existing agreement. No additional details on scope or value are provided in the announcement.

Dec 2024Advanced Oxygen Therapy Inc.News article

The Wound Healing Society recommends **topical oxygen therapy** as the highest-level ('Level I') treatment for diabetic foot ulcers (DFUs). This designation highlights its efficacy in managing chronic wounds among diabetic patients. The recommendation aligns with growing clinical evidence supporting advanced wound care solutions.

Dec 2023Advanced Oxygen Therapy Inc.News article

AOTI delivers a keynote address at the **Advanced Wound Care Summit Europe**, a two-day event uniting European wound care leaders. The summit focuses on accelerating innovation, investment, and partnerships to commercialize next-generation wound care solutions. Attendees include industry stakeholders driving advancements in advanced wound care technologies.

Nov 2023Advanced Oxygen Therapy Inc.News article